

## ASX Announcement

### Entitlement Offer Results and Shortfall Notification

**MELBOURNE Australia, 14 June 2019**, AdAlta Limited (ASX: 1AD) is pleased to advise that its non-renounceable entitlement offer (Entitlement Offer) announced on Thursday, 23 May 2019 closed on Wednesday, 12 June 2019.

AdAlta received applications under the Entitlement Offer for 4,868,898 new fully paid ordinary shares amounting to total subscriptions of \$730,334.70. The 8,495,252 new shares that were not taken up under the Entitlement Offer will be allotted to shortfall applicants on the same terms of the Entitlement Offer.

Below is a table outlining the effects of the Entitlement Offer on the capital structure of the Company:

EVENT	NUMBER OF SECURITIES
Shares currently on issue*	137,205,276
Maximum shares offered under the Entitlement Offer	13,364,150
Shares applied for under the Entitlement Offer	2,479,693
Additional shares applied for under the Entitlement Offer	2,389,205
Shares allotted to shortfall applicants	8,495,252
<b>Total shares to be issued under Entitlement Offer</b>	<b>13,364,150</b>

\*13,732,580 shares to be issued as part of Tranche Two which is subject to shareholder approval at EGM on 27 June 2019 as part of \$5million Placement to institutional and sophisticated investors.

AdAlta intends to issue and allot all shares applied for and to apply to ASX for quotation of those shares in line with the Entitlement Offer timetable on or around Monday 17 June.

The number of shares on issue after the issue of entitlement and shortfall shares will be 150,569,426.

It is also noted that a total of 6,682,075 Options will be issued as part of the Entitlement Offer on the basis of 1 option for every 2 new shares subscribed for under the Entitlement Offer (or as part of the shortfall). Each new Option is exercisable at \$0.25 each on or before 30 June 2021.

AdAlta CEO, Sam Cobb said: "We are grateful to have received support from our existing shareholders for this raising. The raising ensures that AdAlta is funded to hit several key value inflection points over the next 18 months with our lead candidate, AD-214, and the i-body technology including development of the AdAlta pipeline and progression of several partnering opportunities."

--ends--

## **Notes to Editors**

### **About AdAlta**

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: [www.adalta.com.au](http://www.adalta.com.au).

### **For more information, please contact:**

**AdAlta Limited**  
Sam Cobb, CEO  
Tel: +61 (0)3 9479 5159  
E: [s.cobb@adalta.com.au](mailto:s.cobb@adalta.com.au)

## **Jurisdictional distribution**

This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any security or financial product and neither this announcement nor anything attached to this announcement shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or the solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities may not be offered or sold directly or indirectly in the United States unless they have been registered under the US Securities Act (which AdAlta has no obligation to do or procure) or are offered and sold in a transaction exempt from, or not subject to, the registration of the US Securities Act and any other applicable United States state securities laws.

## **Forward looking statements**

This announcement contains forward looking statements, including statements of current intention, statements of opinion and predictions as to possible future events. Forward looking statements should, or can generally, be identified by the use of forward looking words such as "believe", "expect", "estimate", "will", "may", "target" and other similar expressions within the meaning of securities laws of applicable jurisdictions, and include but are not limited to the expected outcome of the Acquisition. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. Such statements are not statements of fact and there can be no certainty of outcome in relation to the matters to which the statements relate. These forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events or results expressed or implied by such statements. Those risks, uncertainties, assumptions and other important factors are not all within the control of AdAlta and cannot be predicted by AdAlta and include changes in circumstances or events that may cause objectives to change as well as risks, circumstances and events specific to the industry, countries and markets in which AdAlta operates. They also include general economic conditions, exchange rates, interest rates, competitive pressures, selling price, market demand and conditions in the financial markets which may cause objectives to change or may cause outcomes not to be realised.

None of AdAlta or any of its advisors or affiliates (or any of their respective officers, employees or agents) makes any representation, assurance or guarantee as to the accuracy or likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.